Esperion Therapeutics, Inc.
$2.02
0%
2026-04-21 06:42:01
www.esperion.com
NGM: ESPR
Explore Esperion Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$510.15 M
Current Price
$2.02
52W High / Low
$4.17 / $0.69
Stock P/E
—
Book Value
$-1.23
Dividend Yield
—
ROCE
36.51%
ROE
6.57%
Face Value
—
EPS
$-0.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
294
Beta
1.17
Debt / Equity
-0.84
Current Ratio
1.54
Quick Ratio
1.19
Forward P/E
7.4
Price / Sales
1.38
Enterprise Value
$937.43 M
EV / EBITDA
15.53
EV / Revenue
2.33
Rating
Buy
Target Price
$6.99
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
| 2. | Lifecore Biomedical, Inc. | $5.35 | — | $200.6 M | — | -5.74% | -612.08% | $8.98 / $3.62 | $-0.38 |
| 3. | Aurora Cannabis Inc. | $3.72 | — | $285.82 M | — | 1.34% | -15.51% | $9.33 / $4.29 | $6.8 |
| 4. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 5. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 6. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 7. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 168.45 M | 87.31 M | 82.39 M | 65 M | 69.11 M | — |
| Operating Profit | 85.23 M | -9.96 M | 7.09 M | -22.1 M | -4.42 M | — |
| Net Profit | 61.83 M | -31.33 M | -12.72 M | -40.45 M | -21.32 M | — |
| EPS in Rs | 0.24 | -0.12 | -0.05 | -0.16 | -0.08 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 403.13 M | 332.31 M | 116.33 M | 75.47 M |
| Operating Profit | 60.27 M | 54.4 M | -155.56 M | -179.5 M |
| Net Profit | -22.68 M | -51.74 M | -209.25 M | -233.66 M |
| EPS in Rs | -0.09 | -0.2 | -0.81 | -0.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 465.89 M | 343.82 M | 205.8 M | 247.94 M |
| Total Liabilities | 767.85 M | 732.54 M | 660.79 M | 571.72 M |
| Equity | -301.96 M | -388.72 M | -454.99 M | -323.78 M |
| Current Assets | 462.57 M | 338 M | 201.06 M | 246.68 M |
| Current Liabilities | 300.81 M | 246.23 M | 156.22 M | 92.31 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.09 M | -23.65 M | -135.49 M | -174.83 M |
| Investing CF | 0 M | -0.32 M | 42.5 M | 8.1 M |
| Financing CF | 36.18 M | 86.48 M | 50.46 M | 32.61 M |
| Free CF | -13.09 M | -23.97 M | -135.49 M | -174.83 M |
| Capex | — | -0.32 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 21.31% | 185.66% | 54.14% | — |
| Earnings Growth % | 56.17% | 75.27% | 10.45% | — |
| Profit Margin % | -5.63% | -15.57% | -179.87% | -309.58% |
| Operating Margin % | 14.95% | 16.37% | -133.72% | -237.83% |
| Gross Margin % | 67.95% | 79.36% | 62.81% | 64.27% |
| EBITDA Margin % | 15.84% | 2.28% | -129.03% | -233.65% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.